for future analysis. The majority of short-term readmissions are related to the index procedure; however, long-term readmission rates are related to systemic comorbidities. Targeted patient interventions may improve readmission rates, particularly in those with nonprivate insurance.
test.
Results: There were no significant demographic differences (age, gender, risk factors for wound complication) between the two high-risk groups. In low-risk controls, the major wound complication rate was 4.8% (1 infection in 21 incisions, average Szilagyi class 2), resulting in a 3.8-day LOS, 4.8% ROR, 4.8% readmission rate, and $17,599 in average cost. For high-risk controls, there was a significant increase in major wound complications (21.7% including 15 infections in 60 incisions, average Szilagyi class 2.4), LOS (10.6 days), ROR (18.3%), readmission (16.7%), and costs ($36,537) . Finally, negative-pressure therapy significantly reduced major wound complications (8.5%, including 6 infections in 59 incisions, average Szilagyi class 2.33; P < .001), ROR (8.5%; P < .05), readmission (6.8%; P < .04), and cost ($30,492; P ¼ .11) in the high-risk group but not LOS (10.6 days). Use of the device, costing $500, was associated with a reduction in mean total inpatient cost per patient of $6045 in this study.
Conclusions: This study suggests negative-pressure therapy significantly reduces the major complication rate, ROR, readmission, and hospital costs for patients at high-risk for groin wound complications. Global health care costs may be reduced further considering savings in reduced outpatient treatment of infection and readmission penalties. We recommend negative-pressure therapy for all groin incisions at high-risk for complications.
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Analysis of Dorsalis Pedis
Methods: We reviewed all patients at our institution undergoing either DPB between 2000 and 2014 or tibial PTA/S between 2004 and 2014. For direct comparison, we restricted analyses to procedures performed after 2003, excluded patients who had undergone any prior ipsilateral bypass, and included only PTA/S limbs that were suitable bypass candidates, had TASC C or D disease, and had a potential distal anterior tibial or dorsalis pedis bypass target on angiography. Outcomes included perioperative complications, restenosis (>3.5Â step-up by duplex), reintervention, patency, limb salvage, and survival. Predictors were identified using Kaplan-Meier survival estimates and Cox proportional hazard models. Objectives: Outpatient use of atherectomy has grown rapidly in recent years, particularly in the physician office setting. Outcomes of this practice are poorly understood. Our study evaluated real world results of atherectomy done for claudication for infrainguinal occlusive disease. We looked at the downstream results of intervention done in the office setting compared to the hospital outpatient setting.
Methods: Analysis of Medicare Part B procedure and claims data summary from 2012 to 2014 using the 5% samples were recorded. The longitudinal analysis assessed upstream utilization 18 months before the incident atherectomy procedure, services rendered during the incident peripheral vascular intervention (PVI), and utilization up to 12 months after the incident PVI. Incident events were identified between January 1, 2012, and June 30, 2013. We used a rolling 12-month downstream time frame to tag other events associated with the beneficiary. Analyses were limited to "incident" procedures of femoral-popliteal atherectomy (Current Procedural Terminology code 37225) or tibial-peroneal atherectomy (code 37229). For each downstream service, we calculated the percentage of unique patients receiving that service.
Results: We analyzed 924 patients undergoing femoral-popliteal atherectomy (262 office-based and 662 hospital outpatient-based). Of these, 40.1% and 31.6% of femoral-popliteal atherectomy patients in the office-based and hospital outpatient-based groups, respectively, had repeat PVI within 1 year of their incident procedure. Need for any lower extremity amputation was 2.7% in the office-based group and 4.8% in the hospital outpatient group. Major amputation was performed in 1.9% and 2.9% of patients, respectively (Table I) . A total of 423 patients undergoing tibial-peroneal atherectomy were analyzed (202 office-based and 221 hospital outpatient-based). Of these, 44.6% and 34.8% of tibialperoneal atherectomy patients in the office-based and hospital outpatient-based groups, respectively, had repeat PVI within 1 year of their incident procedure. Need for any lower extremity amputation was 4.4% and 10.4% in the office-based group and 4.8% in the hospital outpatient group. Major amputation was performed in 3.0% and 7.2% of patients, respectively (Table II) .
Conclusions: We believe this is the first time that Medicare claimsbased utilization data for atherectomy procedures and repeat procedures among patients being treated for claudication have been compared across office-based and hospital outpatient-based cohorts. Considering the high rate of amputation in both hospital outpatient and physician office settings, the data suggest that atherectomy for occlusive disease in the femoral-popliteal and tibial-peroneal segments 
